FDA grants accelerated approval to Rybrevant Faspro for head and neck cancer

The FDA grants accelerated approval to Rybrevant Faspro for previously treated head and neck cancer; plus Novartis confirms tumor reports after Zolgensma and Wisconsin records its first measles death since 1990.